Application 218691
- Type
- ANDA
- Sponsor
- FDC LTD
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | CEFIXIME | CEFIXIME | FOR SUSPENSION;ORAL | 100MG/5ML | No | No |
| 002 | CEFIXIME | CEFIXIME | FOR SUSPENSION;ORAL | 200MG/5ML | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A218691-001 | CEFIXIME | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | AB | 2026-05-14 | |
| A218691-002 | CEFIXIME | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | AB | 2026-05-14 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A218691-001 | AB |
| A218691-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218691-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | AB | 2026-05-14 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218691-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | AB | 2026-05-14 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218691-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218691-002 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CEFIXIME | CEFIXIME | REMEDYREPACK INC. | 3194433c-c04e-442b-9668-fbeb0a15bac7 | 2026-08-05 | Warnings, Adverse reactions | CEFIXIME CEFIXIME |
| CEFIXIME | CEFIXIME | REMEDYREPACK INC. | d6718f02-8eea-4c2f-9aa2-65121d9a6e4c | 2026-07-28 | Warnings, Adverse reactions | CEFIXIME CEFIXIME |
| Cefixime | CEFIXIME | Rising Pharma Holdings, Inc. | b5a3c547-3bc7-4856-af9c-1bead294f5d9 | 2026-04-06 | Warnings, Adverse reactions | Cefixime CEFIXIME |
| Cefixime | CEFIXIME | Aurobindo Pharma Limited | 9cdb156f-7a99-413e-b49a-ffafaf9e93fe | 2026-03-25 | Warnings, Adverse reactions | Cefixime CEFIXIME |
| Cefixime 400 mg | CEFIXIME | Health Department, Oklahoma State | f0fdb14b-e4fb-707e-e053-2a95a90a9049 | 2025-12-20 | Warnings | CEFIXIME |
| CEFIXIME | CEFIXIME | Lupin Pharmaceuticals, Inc. | 6d68dbd9-7d75-4ff1-91db-79ff8ae879ec | 2025-10-14 | Warnings, Adverse reactions | CEFIXIME CEFIXIME |
| Cefixime | CEFIXIME | Aurobindo Pharma Limited | 068e6edd-a5fe-40d8-8dcf-ac82b78dced4 | 2024-02-14 | Warnings, Adverse reactions | Cefixime CEFIXIME |
| CEFIXIME | CEFIXIME | Ascend Laboratories, LLC | 6f1df975-f825-4301-87da-d7eba56a6890 | 2022-05-31 | Warnings, Adverse reactions | CEFIXIME CEFIXIME |